Aims To determine whether there is an association between use of fluoroquinolones and tendinitis in a large population under everyday circumstances. Methods A retrospective cohort study was carried out in a dynamic population. Data came from the IPCI-database which consists of all data on consultations, morbidity, prescriptions and other interventions, as registered by GPs in a source population of approximately 250 000 persons. For this study data were collected from 41 general practices in the period from January 1st, 1995 through December 31st, 1996. All persons treated with either fluoroquinolones, amoxicillin, trimethoprim, cotrimoxazole or nitrofurantoin were followed from the first day of treatment until the outcome of interest, death, transfer to another practice, or end of the study period, whichever came first. The risk window was defined as the legend duration +1 month. Potential cases were defined as a registration of a tendinitis or tendon rupture. Patients with a history of tendinitis or tendon rupture, preceding trauma or inadequate diagnoses were excluded on the basis of a review of the patient profiles and additional clinical data, blinded as to the exposure status. Results were adjusted for age, gender, concurrent corticosteroid exposure and number of GP visits. Results There were 1841 users of fluoroquinolones and 9406 users of the other antibacterial drugs with an average duration of 9 and 7 days, respectively. Tendinitis or tendon rupture was registered in 97 profiles, but after review only 22 complied with the case definition. The adjusted relative risk of tendinitis to fluoroquinolones was 3.7 (95%CI: 0.9-15.1) for Achilles tendinitis and 1.3 (95%CI: 0.4-4.7) for other types of tendinitis. Achilles tendinitis to ofloxacin had a relative risk of 10.1 (95%CI: 2.2-46.0) and an excess risk of 15 cases per 100 000 exposure days. Conclusions Although the numbers in our study are small, our results suggest that some fluoroquinolones may increase the risk of Achilles tendinitis, and that this risk increase is highest for ofloxacin.
Introduction tendinitis has been attributed to fluoroquinolones, the epidemiological confirmation of the association is scanty. In the past few years, there has been a marked increase in the number of spontaneous reports of tendinitis In order to assess whether there is an association between fluoroquinolones and tendinitis, and to determine the associated with fluoroquinolones [1] [2] [3] [4] [5] [6] [7] . In the vast majority of cases, the Achilles tendon was affected with incidence and relative risk of tendinitis to the different products, we conducted a retrospective cohort study in a symptoms compatible with painful tendinitis or with rupture, usually during the first 2 weeks of treatment.
large population under everyday circumstances. Fluoroquinolones form a relatively new class of antibacterial agents which act by inhibiting bacterial DNA gyrase [8] . The most frequently observed adverse effects Methods are of gastro-intestinal origin, followed by CNS disorders Data source with data from computerized patient records of general calculated as the sum of the legend durations, corrected for refill prescriptions. The risk period was defined as the practitioners (GPs) throughout the Netherlands which was developed by the Department of Medical Informatics exposed period plus 1 month. The month was added because any increased risk during exposure will have a of the Erasmus University Medical School. The database includes all demographic information, patient complaints, carry-over effect and because a notification in GP-records may be delayed when patients present themselves with symptoms, laboratory tests, diagnoses, discharge and consultant letters, and prescription details (including drug tendinitis several days after onset. Concomitant users of fluoroquinolones and one of the reference drugs during name, dosage form, dose, quantity prescribed, and indication). GPs write the prescriptions directly from the this risk period were excluded. To ensure maximal sensitivity and specificity, we computer, thus ensuring automatic recording. Medication codes are based on the national database of drugs, followed a two-step selection procedure of case-finding (step 1) and case-validation (step 2). In step 1, potential maintained by the Royal Dutch Association for the Advancement of Pharmacy. A modification of The cases of the outcome of interest were defined as the registration of one or more of the diagnoses or symptoms International Classification for Primary Care [9] is the coding system employed for patient complaints, diagnoses, mentioned in Table 1 within the risk period. Moreover, all records were studied for a notification of 'tendinitis', and indications but these can also be entered as free text. At present, the IPCI-project monitors a population of 'tendon disorder', 'tendon rupture', 'coup de fouet' or 'pain upper leg' in the free text of each patient file. In about 250 000 patients on a continuous basis. The data used for this study were collected from 41 general step 2, for all selected patients a patient profile was generated and printed, where all prescriptions, GP medical practices in the period between January 1st, 1995 and December 31st, 1996.
diagnoses, laboratory results, hospital referrals and GP remarks were listed. The exposure to the study drugs in these patient profiles was blinded. Following an indepenCohort definition dent review of the patient profile by two GPs, patients were excluded if the patient had a history of tendinitis or The cohort consisted of all patients of 15 years and older with a permanent status who were treated in the study tendon rupture before use of the study drugs, if another cause of the tendinitis was likely (e.g. trauma), or if the period with one of the following antibacterial drugs: fluoroquinolones (index group), amoxicillin, trimethodiagnosis was wrong (e.g. bursitis). In case of disagreement, the data were independently reviewed by a third prim, cotrimoxazole and nitrofurantoin (reference group). The latter four drugs were chosen as a reference because medical practitioner. To confirm the adequacy of the validation procedure, the GPs of potential cases were these are commonly used drugs with a well-known safety profile, and have not been associated with tendinitis. sent a questionnaire requesting details of some of the clinical features and any correspondence available related Subjects had to have a computer-recorded history of at least 3 months duration prior to the date of first prescription in order to be eligible to participate in this study. All coded prescriptions were considered with the dose. The total exposed period of each subject was to the diagnosis of interest. All patients' personal identifiers After more extensive review of the computerized profiles of these potential cases by the medical reviewers, 68 were suppressed before sending.
(70%) cases were excluded from further analysis: 26 (38%) because the diagnosis was not tendinitis but mostly Analysis bursitis, 12 (18%) because tendinitis was probably caused by a trauma and 30 (44%) because there was a history of The first outcome-related event that occurred was used in the analyses. The incidence density (ID) was calculated tendinitis or tendon rupture before intake of the study drugs. Concerning the remaining 29 cases, questionnaires by dividing the number of events occurring in the risk windows by the total risk period, and was expressed as were sent to the GPs which were all returned after some reminders. After blinded review, 7 additional patients the number of events per 100 000 days at risk. Incidence densities for exposure to fluoroquinolones were compared were excluded: 2 cases because the diagnosis was not tendinitis, and 5 because tendinitis was caused by trauma. with those for the reference drugs. The relative risk (RR) of tendinitis was calculated as an incidence density Consequently, 22 cases (all tendinitis; no rupture) complied with the case definition. In 8 of these patients, ratio, dividing the two incidence densities. The excess risk was calculated by subtracting the incidence densities the Achilles tendon was affected. Of the 22 cases, 7 occurred during fluoroquinolones and 15 during use of a in index and reference group. Confidence (95%) intervals for the crude and adjusted relative risks were estimated reference drug. The incidence density of tendinitis during fluoroquinolones was 7.74 per 100 000 days at risk and with Poisson regression analysis. Adjusted estimates of the RR were controlled for the potentially confounding 3.27 for the reference drugs, which is compatible with a RR of 2.4 (95% CI: 0.96-5.80). Ofloxacin had a effects of gender, age, number of GP visits and concurrent corticosteroid use.
significantly increased crude RR of tendinitis of 6.5 (95%CI: 2.14-19.45), which declined after adjustment to 4.9 (95%CI: 1.57-15.06). No significant association was Results found for ciprofloxacin and norfloxacin (Table 3) . After stratification for Achilles tendinitis and other types of In the study period, 11 812 patients of 15 years and older received 18 428 prescriptions for the study drugs. Of tendinitis, fluoroquinolones as a group had an elevated RR of Achilles tendinitis of 4.4 (95% CI: 1.27-20.27), these, 786 patients were excluded because dosage was unknown (n=34), because of concomitant use of which declined after adjustment to 3.7 (95% CI: 0.93-15.14), while no association was found for the fluoroquinolones and the reference drugs in the risk period (n=653) or because they were chronic user (n= other types of tendinitis. Ofloxacin was associated with an increased RR of 10.1 for Achilles tendinitis (95% CI: 99). Furthermore, 226 patients were excluded because they had a history of rheumatoid arthritis (n=76), SLE 2.20-46.04), whereas no association was found with the other types of tendinitis for the different fluoroquinolone (n=3), polymyalgia rheumatica (n=28), gout (n=118) or AIDS (n=1). Hence, the study population consisted agents (Table 3 ). The risk difference between fluoroquinolones and the reference drugs was 4 cases per of 10 800 patients. During the study period, there were 1841 users of fluoroquinolones and 9406 users of the 100 000 days for tendinitis, and 4 cases per 100 000 days for Achilles tendinitis. Ofloxacin was associated with a other antibacterial drugs (fluoroquinolones as well as one of the reference drugs may have been prescribed to the risk increase of 15 cases per 100 000 days. A duration-or dose effect relationship could not be assessed as almost all same patient outside the risk period), with an average duration of 9 and 7 days, respectively (Table 2 ). In total, courses were given for similar short periods and because the large majority of fluoroquinolone users took the 418 patients received 500 prescriptions for ofloxacin, 456 patients received 556 prescriptions for ciprofloxacin and recommended daily dose. 1030 patients received 1362 prescriptions for norfloxacin, with an average duration of 10, 9 and 8 days, respectively. Discussion Most index and reference drugs were used for urinary or respiratory tract infections at the recommended daily
In this study, we found that the risk of tendinitis with fluoroquinolones was higher than the risk with a reference dosage. There was no significant difference in indication between index and reference group. The reference group group of four commonly used antibacterial agents with a known safety profile. As these are not known to cause consisted of relatively more female patients. The mean age in the index group was higher; patients in the index tendinitis, they represent the background risk and even if some actually cause tendinitis, this would tend to group visited the GP more often, and had a higher prevalence of renal failure (Table 2) . During the total risk underestimate the RR of fluoroquinolones. Ofloxacin had the strongest association with Achilles tendinitis. period of 548 919 days, possible cases of tendinitis or tendon rupture were registered in 97 patient profiles.
Although age, gender, and number of visits to the GP differed significantly between the fluoroquinolone users contra-indication for fluoroquinolones selection bias is unlikely. One of the advantages of a study using and the users of other antibacterial drugs, adjustment for these factors did not eliminate the association with automated GP data is that information on disease and exposure are gathered by GPs who are not aware of the tendinitis. None of the cases had renal failure, which has been suggested as a possible risk factor for tendinitis [7] . research hypothesis at the time of registration. Hence recall bias or other types of information bias are not very Use of corticosteroids, a suggested risk factor for tendon rupture, was not related to tendinitis in this study.
likely in this study. To avoid observer bias we conducted a review of the patient profiles which was blinded to The validity of epidemiological studies may be endangered by selection bias, information bias, or confounding. exposure status. Another important aspect concerning the validity of follow-up studies with automated data resources As the association between fluoroquinolones and tendinitis was only recently widely recognized and as proven risk is the proportion of unidentified eligible cases (false negatives) through the initial computerized search. We factors for tendinitis, such as physical training, are not a have tried to minimize this problem by performing not acin, is higher than the risk to the other antibacterial drugs. To our knowledge, this is the first epidemiological only a search on a wide range of ICPC-codes but also a text string search in the database. This explains in part study which demonstrates an increased risk. It should be emphasized, however, that the absolute numbers in our why only 22 out of 97 possible cases passed the validation procedure. In the IPCI-project information is gathered study are small and that an extra number of cases of Achilles tendinitis of 15 per 100 000 days may be only from GPs who are fully automated and do not use paper resources. Even if cases of tendinitis have acceptable when prescribed for severe infections. been misclassified, misclassification was probably random. Hence, this will not affect the RR in a cohort study References but might have some effect on the risk difference. persons. The average time between the start of the
